Sirona Biochem (STU:ZSB) EBIT: €-1.54 Mil (TTM As of Jul. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sirona Biochem EBIT?

Sirona Biochem STU:ZSB EBIT is €-1.54 Mil as of Jul. 2024.

Sirona Biochem's earnings before interest and taxes (EBIT) for the three months ended in Jul. 2024 was €-0.45 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jul. 2024 was €-1.54 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sirona Biochem's annualized ROC % for the quarter that ended in Jul. 2024 was -192.90%. Sirona Biochem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 was -89,400.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sirona Biochem's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jul. 2024 was -48.43%.

Sirona Biochem  (STU:ZSB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sirona Biochem's annualized ROC % for the quarter that ended in Jul. 2024 is calculated as:

ROC % (Q: Jul. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2024 ) + Invested Capital (Q: Jul. 2024 ))/ count )
=-1.792 * ( 1 - 0% )/( (0.821 + 1.037)/ 2 )
=-1.792/0.929
=-192.90 %

where

Invested Capital(Q: Apr. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.491 - 0.624 - ( 0.018 - max(0, 1.442 - 0.488+0.018))
=0.821

Invested Capital(Q: Jul. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.544 - 0.562 - ( 0.022 - max(0, 1.598 - 0.543+0.022))
=1.037

Note: The Operating Income data used here is four times the quarterly (Jul. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sirona Biochem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jul. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Apr. 2024  Q: Jul. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.788/( ( (0.003 + max(-0.611, 0)) + (0.001 + max(-0.554, 0)) )/ 2 )
=-1.788/( ( 0.003 + 0.001 )/ 2 )
=-1.788/0.002
=-89,400.00 %

where Working Capital is:

Working Capital(Q: Apr. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.008 + 0 + 0.0039999999999999) - (0.624 + 0 + -0.0010000000000001)
=-0.611

Working Capital(Q: Jul. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.003 + 0 + 0.005) - (0.562 + 0 + 0)
=-0.554

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sirona Biochem's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jul. 2024 )
=-1.54/3.180
=-48.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sirona Biochem EBIT Related Terms

Sirona Biochem EBIT Historical Data

* Premium members only.

The historical data trend for Sirona Biochem's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sirona Biochem EBIT Chart

Sirona Biochem Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.04 -2.66 -1.60 -2.61 -1.62

Sirona Biochem Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.35 -0.45 -0.29 -0.45

STU:ZSB vs MTNB, TCRT, QLGN: EBIT Comparison

For the Biotechnology subindustry, Sirona Biochem's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sirona Biochem EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirona Biochem's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sirona Biochem's EV-to-EBIT falls into.


Sirona Biochem EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-1.54 Mil mean?
Sirona Biochem (STU:ZSB) has a EBIT of €-1.54 Mil as of Jul. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sirona Biochem.
Is Sirona Biochem's EBIT too high?
Sirona Biochem's current EBIT is €-1.54 Mil.
How does Sirona Biochem's EBIT compare to MTNB and TCRT?
Sirona Biochem's EBIT of €-1.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sirona Biochem. Sirona Biochem's current EBIT is €-1.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sirona Biochem stock overvalued right now?
Sirona Biochem (STU:ZSB) has a current EBIT of €-1.54 Mil. The current EBIT is €-1.54 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sirona Biochem (STU:ZSB), the current EBIT is €-1.54 Mil as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sirona Biochem Business Description

Address C/o WeWork, 595 Burrard Street, Vancouver, BC, CAN, V7X 1L4
Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. The company has a business presence in Canada and France.